TXG
10x Genomics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Ample Liquidity
High Gross Profit Margin
Price Hits New Low
Price Hits 52-week Low
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TXG
10x Genomics, Inc.
A life sciences leader that develops instruments, consumables and software for analyzing biological systems complexity of biology
Life Science Tools and Services
07/02/2012
09/12/2019
NASDAQ Stock Exchange
1,306
12-31
Common stock
6230 Stoneridge Mall Road, Pleasanton, California 94588
--
10x Genomics, Inc., was incorporated in Delaware on July 2, 2012. The Company started commercial and manufacturing operations and sales of its instruments and consumables in 2015. The company's integrated solutions include the company's Chromium instruments, its enzymes, reagents, microfluidic chips and other consumables, and software for analyzing biological systems.
Earnings Call
Q1/2025
Estimate EPS-0.29
Actual EPS-0.28
Estimate Revenue132.51M
Actual Revenue154.90M
10x Genomics Q1 2025: Navigating Contradictions in Customer Uncertainty, NIH Funding, and Margin Expectations
May 19,2025 03:57
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TXG has released its 2025 Q3 earnings. EPS was reported at -0.22, versus the expected -0.07, missing expectations. The chart below visualizes how TXG has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TXG has released its 2025 Q3 earnings report, with revenue of 149.00M, reflecting a YoY change of -1.75%, and net profit of -27.47M, showing a YoY change of 23.16%. The Sankey diagram below clearly presents TXG's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
